Drug intelligence / Profile preview

zidovudine + stavudine + didanosine + lamivudine

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of four nucleoside reverse transcriptase inhibitors (NRTIs) used in the treatment of HIV-1 infection. While these drugs have been studied in various dual combinations, the use of all four together is not a standard therapeutic approach. Some combinations, particularly stavudine and didanosine, have been associated with enhanced toxicity including increased risk of fatal and nonfatal cases of lactic acidosis, pancreatitis, peripheral neuropathy, and hepatotoxicity.

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on zidovudine + stavudine + didanosine + lamivudine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zidovudine + stavudine + didanosine + lamivudine.

Explore the full profile